Facial Wrinkles News and Research

RSS

Botox for asthma

Botox, or botulinum toxin type A, which is best-known for smoothing away facial wrinkles is to be tested as an asthma treatment at Melbourne's Monash University. A recent survey by the university found that about half of severe asthmatics suffer problems with their voice box as well as their lungs. The problems were similar to vocal cord dysphonia – or loss of voice through overuse – a condition which Botox is frequently used to fix.

29 Jun 2011

Suneva Medical receives Health Canada marketing approval for Bellafill

Suneva Medical, a privately-held aesthetic medical device company, today announced the expansion of its core aesthetics injectable business with approval from Health Canada to market Bellafill™, its long lasting dermal filler for nasolabial folds or smile line correction.

29 Jun 2011

Cynosure announces acquisition of HOYA ConBio's aesthetic laser business

Building on its reputation as a global technology leader in laser and light-based aesthetic systems, Cynosure, Inc. today announced that it has acquired the assets of the aesthetic laser business of HOYA ConBio, a wholly owned subsidiary of Japan-based HOYA Corporation, for $24.5 million in cash. HOYA ConBio is based in Fremont, California.

28 Jun 2011

Healthy diet, antioxidants, critical nutrients and activities may provide the foundation to youthful living

As the baby boomer generation continues to increase in age, so does its passion to remain youthful, both inside and out. Beating the clock is now a multi-faceted, science-driven industry. From its age-old quests to find the elixir of life, to modern exploration of how microcellular activity contributes to metabolic breakdown, scientific research continues to advance its goals to enhance bodily energy, vigour and performance, and fade or stall the visible signs of aging.

16 Jun 2011

EndyMed's 3DEEP RF technology in real-time skin impedance measurements published in peer reviewed paper

EndyMed Medical, Ltd., a leader in the use of multi-source radiofrequency for professional aesthetic treatments, announced today the publication of the latest peer reviewed paper on 3DEEP radiofrequency technology, "A novel method for real-time skin impedance measurement during radiofrequency skin tightening treatments".

24 Mar 2011

Botox Cosmetics increase overall quality of life and self-esteem

Chicago Facial Plastic Surgeon, Steven H. Dayan, MD, FACS, publishes a study in the November 2010 issue of Dermatologic Surgery, a prominent Dermatology journal, demonstrating that increases in overall quality of life and self-esteem were observed in participants treated with Botulinum Toxin Type A or Botox Cosmetic. In this double-blind randomized placebo-controlled survey, Dr. Dayan and DeNova research worked with one hundred participants who were treated with either Botox Cosmetic or a saline placebo for facial wrinkles.

23 Nov 2010

Oxygen Biotherapeutics 2010 first quarter net loss increases to $3 million

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) first quarter ended July 31, 2010.

10 Sep 2010

Study shows DERMACYTE Oxygen Concentrate improves skin appearance

Oxygen Biotherapeutics, Inc. today announced that results from an 8-week cosmetic study showed that the topical application of DERMACYTE Oxygen Concentrate, an oxygen-rich skin care lotion, appears to improve the appearance of fine lines and the perception of skin appearance.

31 Aug 2010

Anika second-quarter product revenue increases 56% to $13.7 million

Anika Therapeutics, Inc., a leader in products for tissue protection, healing, and repair, based on hyaluronic acid technology, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Anika to defend patent infringement lawsuit for MONOVISC product

Anika Therapeutics, Inc., a leader in products for tissue protection, healing and repair, based on hyaluronic acid technology, announced today that they had been served with a complaint alleging patent infringement with respect to the MONOVISC product by Genzyme Corporation.

13 Jul 2010

Botox reduces short-term pain in thoracic outlet syndrome patients

Made popular for its ability to smooth wrinkles when injected into the face, Botox - a toxin known to weaken or paralyze certain nerves and muscles - may have another use that goes beyond the cosmetic.

11 Jun 2010

Contura submits PMA for Aquamid

Contura Inc. has submitted a Premarket Approval Application for Aquamid to the U.S. Food and Drug Administration requesting marketing approval in the U.S. for the aesthetic treatment of moderate to severe facial wrinkles and folds.

16 Apr 2010

FDA approves Allergan's JUVÉDERM XC dermal filler

Allergan, Inc. today announced the U.S. Food and Drug Administration’s (FDA) approval of JUVÉDERM® XC, a new formulation of the currently FDA-approved JUVÉDERM® dermal filler and the latest advancement in hyaluronic acid (HA) dermal fillers.

1 Feb 2010

Anika Therapeutics acquires Fidia Farmaceutici subsidiary FAB

Anika Therapeutics, Inc. today announced that it has acquired Fidia Advanced Biopolymers, s.r.l. (“FAB”), a wholly-owned subsidiary of privately held Italian pharmaceutical company, Fidia Farmaceutici S.p.A. FAB provides hyaluronic acid-based (“HA”) products in several therapeutic areas including for the regeneration of connective and structural tissues damaged by injuries, aging or degenerative diseases.

3 Jan 2010

Anika Therapeutics' "ELEVESS Light" receives European CE Mark approval

Anika Therapeutics, Inc., a leader in products for tissue protection, healing and repair based on hyaluronic acid (“HA”) technology, today announced that it has received European CE Mark approval for “ELEVESS™ Light,” the Company’s latest aesthetic product used for the treatment of fine lines and facial wrinkles. ELEVESS Light will be distributed in the European market by the Company’s current aesthetic dermatology distributors.

19 Nov 2009

Lumenis announces launch of the AcuPulse Fractional CO2 Laser System for Aesthetics

Lumenis Inc., a global developer, manufacturer and seller of laser, light-based and radio-frequency devices for surgical, aesthetic, and ophthalmic applications, announced today the launch of the AcuPulse(TM) Fractional CO2 Laser System for aesthetic applications at the American Society of Dermatologic Surgery's annual meeting in Phoenix this week.

From Lumenis Inc. 1 Oct 2009

New treatment for facial wrinkles combines high-intensity light and green tea extract lotion

Scientists in Germany are reporting a major improvement in their potential new treatment for facial wrinkles that could emerge as an alternative to Botox and cosmetic surgery. The non-invasive technique combines high-intensity light from light-emitting diodes (LEDs) and a lotion made of green tea extract. It works ten times faster than a similar anti-wrinkle treatment that uses LEDs alone, the researchers say.

10 Sep 2009

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

In 2008, the global anti-aging skincare market approached $15 billion, with 32 percent of U.S. facial skincare product launches boasting anti-aging claims many over-the-counter products are claiming to achieve comparable benefits as prescription anti-aging treatments.

10 Sep 2009

Health Canada approves Anika Therapeutics' MONOVISC drug

Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.

21 Aug 2009

New discovery on how botulism paralyzes nerve cells

New structures of a botulism toxin interacting with a mimic of the nerve-cell protein it destroys suggest new ways to block this often-fatal interaction. Indeed, the mimic molecules have such high affinity for the toxin and bind to it so tightly that they themselves could possibly serve as anti-toxin drugs with further modification, the researchers said.

21 Jun 2009